Dr Thomas Evans
Vaccitech is a spin-out company from the University of Oxford’s Jenner Institute. Vaccitech is engaged in Phase 2 clinical programs for universal influenza and prostate cancer, Phase 1 for MERS, and preclinical programs for 3 other therapeutic infectious diseases indications.
At the Oxford Science Park close to our founders at the Jenner Institute, and co-located with several other biotechnology companies. This allows for a critical mass of scientists and entrepreneurs.
National & International focus
We work with manufacturers, investigators, and other companies in Europe, Asia (China), Australia and the US. We consider ourselves a global company in both perspective and scope.